| HCPCS | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Drug Class | Minor Drug Class | Oral (Y/N) | FDA Approval Year | FDA Discontinuation Year | CMS Effective Date | CMS Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| C9416 | BCG | BCG, Intravesical | Per instillation | Immunotherapy | Biological Response Modifier | Live Vaccine | No | 1990 | Jan 1, 2004 | Dec 31, 2003 | No Longer Used | |
| J9173 | Durvalumab | Imfinzi | 10mg | Immunotherapy | Checkpoint Inhibitor | PD-L1 | No | 2017 | Jan 1, 2019 | In Use | ||
| J9285 | Olaratumab | Lartruvo | 10 mg | Immunotherapy | Monoclonal Antibody | PDGFR | No | 2016 | Apr 1, 2017 | In Use | ||
| Q5126 | Bevacizumab-maly | Alymsys | 10mg | Immunotherapy | Monoclonal Antibody | VEGF | No | 2022 | Nov 28, 2022 | In Use | ||
| J9176 | Elotuzumab | Empliciti | 1 mg | Immunotherapy | Monoclonal Antibody | SLAMF7 | No | 2015 | Jan 1, 2017 | In Use | ||
| Q5129 | Bevacizumab-adcd | Vegzelma | 10mg | Immunotherapy | Monoclonal Antibody | VEGFR | No | 2023 | Mar 17, 2023 | In Use | ||
| J9302 | Ofatumumab | Arzerra | 10mg | Immunotherapy | Monoclonal Antibody | CD20 | No | 2009 | Jan 1, 2011 | In Use | ||
| J9298 | Nivolumab & Relatlimab-rmbw | Opdualag | 3mg/1mg | Immunotherapy | Checkpoint Inhibitor, Monoclonal Antibody | PD-1, LAG3 | No | 2022 | Sep 27, 2022 | In Use | ||
| J9228 | Ipilimumab | Yervoy | 1mg | Immunotherapy | Checkpoint Inhibitor | CTLA-4 | No | 2011 | Jan 1, 2012 | In Use | ||
| C9082 | Dostarlimab-gxly | Jemperli | 100mg | Immunotherapy | Checkpoint Inhibitor | PD-1 | No | 2021 | Sep 27, 2021 | Jan 26, 2022 | No Longer Used | |
| C9303 | Zolbetuximab-clzb | Vyloy | 1mg | Immunotherapy | Monoclonal Antibody | CLDN18.2 | No | 2024 | Mar 26, 2025 | Jul 9, 2025 | No Longer Used | |
| J9030 | Bacillus calmette-guerin | BCG Vaccine, Tice BCG | 1mg | Immunotherapy | Biological Response Modifier | Live Vaccine | No | 1990 | Jul 1, 2019 | In Use | ||
| A9534 | Tositumomab | Bexxar, Iodine i-131 Tositumomab, therapeutic | per MC | Immunotherapy, Radiopharmaceutical | Radioimmunotherapy | CD20 | No | 2003 | 2014 | Jul 1, 2003 | In Use | |
| A9545 | Tositumomab | Bexxar, Iodine i-131 Tositumomab, therapeutic | Per treatment dose | Immunotherapy, Radiopharmaceutical | Radioimmunotherapy | CD20 | No | 2003 | 2014 | Jan 1, 2006 | In Use | |
| J2930 | Methylprednisolone Sodium Succinate | A-Methapred, SOLU-medrol | 125 mg | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | No | 1959 | Jan 1, 1997 | Apr 17, 2024 | No Longer Used | |
| J1710 | Hydrocortisone Sodium Phosphate | Hydrocortone | 50 mg | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | No | 1960 | 2004 | Jan 1, 1982 | In Use | |
| J1010 | Methylprednisolone acetate | Methylprednisolone acetate | 1mg | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | No | 1959 | Apr 17, 2024 | In Use | ||
| NA | Ketoconazole | Apo-Ketoconazole | 200 mg | Hormonal Therapy | Androgen Receptor Inhibitor | Imidazole Derivative | Yes | 1981 | In Use | |||
| J1050 | Medroxyprogesterone Acetate | Depo-Provera, Depo-SubQ Provera, Provera | 1 mg | Hormonal Therapy | Progestin | No | 1959 | Jan 1, 2013 | In Use | |||
| NA | Estradiol | Estrace | 0.5mg | Hormonal Therapy | Estrogen | Yes | 1998 | In Use | ||||
| NA | Hydrocortisone | Cortef | 5mg, 10mg, 20mg | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Yes | 1952 | In Use | |||
| S0179 | Megesterol | Megace | 20 mg | Hormonal Therapy | Progestin | Yes | 2002 | In Use | ||||
| NA | Estrogens, Esterified | Covaryx, Covaryx H.S., Menest, Ogen, Ortho-Est | 1.25 mg | Hormonal Therapy | Estrogen | Yes | 1977 | In Use | ||||
| J9217 | Leuprolide Acetate | Eligard, Lupron Depot, Viadur, Lupron | 7.5 mg | Hormonal Therapy | GnRH Agonist | No | 1989 | Jan 1, 1997 | In Use | |||
| J1729 | Hydroxyprogesterone Caproate | Hydroxyprogesterone Caproate | 10 mg | Hormonal Therapy | Progestin | No | 2011 | Jan 1, 2018 | In Use |
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has
not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in
specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is
truly not available.
Home